Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Small-molecule, orally bioavailable, synthetic nonpeptide GLP-1 receptor agonists can provide an effective pharmacotherapy as an alternative to peptide-based GLP-1 receptor agonists, without a need for injection.120,121”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [121]
In the citing paper
“Orforglipron is an oral small molecule GLP-1RA developed jointly by Eli Lilly and Chia Tai Tianqing Pharmaceutical Group.173”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [173]
Citations
Cites
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781
Bytzer, P., Talley, N. J., Leemon, M., Young, L. J., Jones, M. P., & Horowitz, M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.16.1989 · Cited by 632
Self-citationDavies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Self-citationStructural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184
Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management
Du, Y. T., Rayner, C. K., Jones, K. L., Talley, N. J., & Horowitz, M. (2018) · Diabetes Care · doi:10.2337/dc17-1536 · Cited by 180
Self-citation
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Self-citationCho, Y., Kim, S., Kim, P.-K., Jo, M. J., Park, S.-E., Choi, Y., Jung, S. M., & Kang, H. J. (2025) · Biomolecules · doi:10.3390/biom15020291 · Cited by 50
“One notable example of a small molecule GLP-1RA is Orforglipron (LY3502970/OWL833), an oral agent developed by the Eli Lilly and Chia Tai Tianqing Pharmaceuticals Group [108,109].”
Colwill, M., Povlsen, S., Pollok, R., Patel, K., Goodhand, J., Ahmad, T., & Honap, S. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf167 · Cited by 40
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“Editorial analyses emphasize that this nonpeptide oral agent challenges the paradigm that oral therapies cannot replicate injectable GLP-1 RA efficacy [39].”
Influential
Metadata
- Authors
- Nauck, M. A., & Horowitz, M.
- Affiliations
- Universitätsmedizin Greifswald (DE)
- Royal Adelaide Hospital (AU)
- Corresponding author
- Nauck, Michael A
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 402
- Issue
- 10400
- Pages
- 429-431
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4381893369
- Cited by
- 16
- References
- 12
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 2
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- orforglipron, GLP-1 receptor agonists, oral drug delivery, once-daily dosing, type 2 diabetes, glycemic control, weight loss, cardiovascular adverse events, exenatide, liraglutide, dulaglutide, semaglutide
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists. https://app.cochat.ai/papers/10.1016/s0140-6736(23)01201-1
- The paper
- Nauck, M. A., & Horowitz, M. (2023). Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists. The Lancet. https://doi.org/10.1016/s0140-6736(23)01201-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.